Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: A systematic review and network meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13451
Abstract: Novel hormonal agents (NHAs) have significantly improved outcomes in men with advanced prostate cancer. However, it remains unclear whether NHAs are associated with subsequent cognitive impairment. Thus, we sought to perform a network meta‐analysis to… read more here.
Keywords: men advanced; risk cognitive; impairment; cognitive impairment ... See more keywords
‘When I can ride my bike, I think, am I at all as sick as they say?’ An exploration of how men with advanced lung cancer form illness perceptions in everyday life
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Cancer Care"
DOI: 10.1111/ecc.13751
Abstract: Abstract Objective The purpose of this study was to explore how men with advanced lung cancer form perceptions of their illness in everyday life and how this influences perceptions about rehabilitation. Methods Constructivist grounded theory… read more here.
Keywords: lung cancer; men advanced; advanced lung; everyday life ... See more keywords
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for overall survival in men with advanced prostate cancer treated with platinum chemotherapy.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.266
Abstract: 266 Background: Platinum compounds are active in pts with metNEPC/CRPC. The neutrophil-to-lymphocyte ratio (NLR) is a simple clinical metric of systemic inflammation with prognostic and predictive value in advanced PC treated with FDA-approved therapies (doc,… read more here.
Keywords: platinum; men advanced; neutrophil lymphocyte; lymphocyte ratio ... See more keywords
Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0172
Abstract: WHAT IS THIS SUMMARY ABOUT? This is a summary of a research study (known as a clinical trial) called HERO. The HERO study compared how well relugolix and leuprolide worked in lowering blood testosterone to… read more here.
Keywords: hero; prostate cancer; men advanced; advanced prostate ... See more keywords